

# M-LOW<sup>TM</sup>

[Amlodipine besylate]

5mg, 10mg Tablets

## DESCRIPTION

M-LOW (Amlodipine besylate) is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.

Chemically, amlodipine besylate is 3-Ethyl-5-methyl(±)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Its molecular formula is  $C_{28}H_{25}ClN_2O_5 \cdot C_6H_5SO_3S$ .

## COMPOSITION

1. M-LOW Tablets 5mg  
Each tablet contains: Amlodipine.....5mg  
(as amlodipine besylate BP)
2. M-LOW Tablets 10mg  
Each tablet contains: Amlodipine.....10mg  
(as amlodipine besylate BP)

## MECHANISM OF ACTION

The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but amlodipine reduces total ischemic burden by the following two actions:

1. Amlodipine besylate dilates peripheral arterioles and thus reduces the total peripheral resistance against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.
2. The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm.

## INDICATIONS

M-LOW (Amlodipine besylate) is indicated for:

1. The treatment of hypertension.
2. The treatment and prophylaxis of chronic stable angina pectoris.
3. The treatment of confirmed or suspected vasospastic angina (Prinzmetal's or Variant Angina).

M-LOW (Amlodipine besylate) may be used alone or in combination with other antianginal or antihypertensive agents.

## DOSAGE AND ADMINISTRATION

For both hypertension and angina the usual initial dose of M-LOW (Amlodipine besylate) is 5mg once daily which may be increased to a maximum dose of 10mg depending on the individual patient's response. No dose adjustment of M-LOW (Amlodipine besylate) is required upon concomitant administration of thiazide diuretics, beta blockers and angiotensin-converting enzyme inhibitors.

### Geriatric Patients:

The recommended initial dose of M-LOW (Amlodipine besylate) in patients over 65 years of age is 5mg once daily. If required, increasing the dose should be done gradually and with caution.

### Hepatically Insufficient Patients:

Dosage requirements have not been established in patients with impaired hepatic function. Therefore, the dosage should be carefully and gradually adjusted depending on the patient's tolerance and response. A lower starting dose of 2.5mg once daily should be considered.

## DRUG INTERACTIONS

**Cytochrome P450 System:** Dihydropyridine calcium channel blockers undergo biotransformation by the cytochrome P450 system, mainly via CYP3A4 isoenzyme. Co-administration of amlodipine with other drugs which follow the same route of biotransformation may result in altered bioavailability of amlodipine or these drugs.

Dosages of similarly metabolized drugs, particularly those of low therapeutic ratio, and especially in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping concomitantly administered amlodipine to maintain optimum therapeutic blood levels.

**Beta-blockers:** When beta-adrenergic receptor blocking drugs

are administered concomitantly with amlodipine, patients should be carefully monitored since blood pressure lowering effect of beta-blockers may be augmented by amlodipine's reduction in peripheral vascular resistance.

## ADVERSE REACTIONS

Amlodipine besylate therapy is generally well tolerated at doses of up to 10mg/day. Most of the reported reactions are of mild to moderate severity and are related to the drug's vasodilator effect on the periphery. Headache and edema are reported most frequently. Dizziness, flushing, and palpitations also occur and appear to be dose-related. Other adverse reactions that have been reported and do not appear to be dose-related include fatigue, nausea/vomiting, abdominal pain, and drowsiness.

## CONTRAINDICATIONS

- Amlodipine besylate is contraindicated in patients with known sensitivity to dihydropyridines, amlodipine or any other components.
- Amlodipine besylate should not be used in cardiogenic shock, clinically significant aortic stenosis, unstable angina (excluding Prinzmetal's angina).
- Amlodipine besylate is contraindicated in patients with severe hypotension (less than 90mmHg systolic).
- Amlodipine besylate is contraindicated in pregnancy and lactation.
- Amlodipine besylate is not recommended for use in children.

## PRECAUTIONS

**General:** The safety and efficacy of amlodipine in hypertensive crisis has not been established.

**Hepatic function:** When amlodipine is used in hepatically impaired patients, the dosage should be carefully and gradually adjusted depending on the patient's tolerance and response.

**Hypotension:** Careful monitoring of blood pressure is recommended, especially in patients with a history of cerebrovascular insufficiency and those taking medications known to lower blood pressure.

**Peripheral Edema:** Care should be taken to differentiate this peripheral edema from the effects of increasing left ventricular dysfunction.

**Interaction with Grapefruit Juice:** Published data indicates that through inhibition of the cytochrome P450 system, grapefruit juice can increase plasma levels and augment pharmacodynamic effects of some dihydropyridine calcium channel blockers.

## STORAGE AND PRESENTATION:

Store below 30°C. Protect from sunlight and moisture.

M-LOW (Amlodipine besylate) 5mg tablets are available in blister packs of 20's.

M-LOW (Amlodipine besylate) 10mg tablets are available in blister packs of 20's.

Keep out of reach of children.

Please read the contents carefully before use.  
This package insert is continually updated from time to time.

Manufactured by:  
Getz Pharma (Pvt.) Limited, 29-30/27,  
K.I.A., Karachi - 74900, Pakistan.

Marketed by:

 SCILIFE

Scilife Pharma (Pvt.) Ltd.,  
16 - K.O.C.H.S., Amir Khusrro Road,  
Karachi - 75350, Pakistan.

LOO-200002375

ایم۔ لو